Table 1 Baseline demographics

Age^a

92

65.29 ± 8.02

64.82 ± 7.81

66.61 ± 8.61

Sex, n female (%)^b

92

39 (42%)

29 (43%)

10 (42%)

Education, median [IQR]^c

92

6 [5–6]

6 [5–6]

6 [5–7]

APOE ε4 carriers, n (%)^b

87

27 (31%)

14 (21%)

13 (62%)*

[¹⁸F]florbetapir BP_ND^c

92

0.16 ± 0.12

0.11 ± 0.05

0.30 ± 0.16*

[¹⁸F]flortaucipir BP_ND^c

44

0.01 ± 0.08

− 0.01 ± 0.05

0.05 ± 0.11*

MTA score^c

92

0.25 [0–1]

0.50 [0–1]

0.00 [0–1]

Fazekas^c

91

0.96 ± 0.82

0.96 ± 0.84

0.96 ± 0.75

Microbleeds, n (%)^b

92

21 (23%)

15 (22%)

6 (25%)

VAT-A^c

92

11.61 ± 0.94

11.62 ± 0.98

11.58 ± 0.83

RAVLT immediate^a

92

44.64 ± 7.68

44.76 ± 7.07

44.29 ± 9.37

RAVLT delayed^a

92

9.00 ± 3.26

9.34 ± 3.02

8.03 ± 3.75

Animal fluency^c

92

24.30 ± 6.22

24.09 ± 6.16

24.92 ± 6.49

TMT-A^c

92

34.89 ± 11.85

34.43 ± 12.11

36.21 ± 11.24

TMT-B^c

92

81.03 ± 40.55

80.93 ± 44.89

81.33 ± 25.21

Stroop I^c

91

43.85 ± 9.06

44.18 ± 10.12

42.92 ± 5.13

Stroop II^c

90

59.48 ± 11.64

60.13 ± 12.49

57.57 ± 8.68

Stroop III^c

90

94.64 ± 22.33

95.61 ± 22.91

91.83 ± 20.79

MMSE^c

92

28.86 ± 1.14

28.93 ± 1.15

28.67 ± 1.13